Immunotherapy is an easiest way for treatment of cervical cancer.

Cells of the cervix become abnormal & starts growing uncontrollably, forming tumors called as cervical cancer. In the United States, this cancer accounts for 6% of all cancers in women and the peak incidence between the age range of 50-55 yrs, across the world, while the second most common cancer in women because about 400,000 cases are newly diagnosed each year. The rate of incidence is higher in developing countries than developed countries. Now, advance cervical cancer can easily be treated with immunotherapy and immune combination therapy and gives positive response.

www.gapsos.com

Causes and risk factors for this cancer are HPV Spreads through sexual intercourse, cause 70% of cases. Other risk factors are having sex in an early age, multiple sexual partners, drugs (diethylstilbestrol) during pregnancy, long term use of birth control pills, compromised immune system, infections with genital herpes, poor living standards, smoking and multiple pregnancies. Infection with HPV increases the risk of cancer by about 80% in women with both infections.

A slow growing cervical cancer that may be asymptomatic in early stages, but symptoms include continuous vaginal discharge (pale, watery, pink, brown, bloody or foul-smelling), abnormal vaginal bleeding between periods, after intercourse or post-menopause Longer and heavier periods than usual.

Several symptom are observed of advanced cervical cancer include loss of appetite and weight loss, fatigue, pelvic pain, back pain, leg pain, single swollen leg, heavy bleeding from the vagina, leakage of urine or feces from the vagina and bone fracture.

This cancer are classified on the basis of histopathology into five types, that involve Squamous cell carcinoma, (85-90%, rise from ectocerv), Adenocarcima (10-15%, rise from endocervix), Adenosquamous, Adenomamalignum, Small cell carcinoma and Neuroendocrine carcinoma.

In immunotherapy, various immunotherapeutic agents are used to treat advanced cervical cancer like monoclonal antibodies (MABs), therapeutic vaccines and many more. Gardasil, Bevacizumab and Cervarix, has received approval by Food and Drug Administration (FDA) for the treatment of cervical cancer. Until much more immunotherapeutic agents such as Ipilimumab, Tumor-Infiltrating Lymphocytes (TIL) and Survivin peptide vaccine are under various phases of clinical trials for FDA approval for the treatment of cervical cancer.

Further more information kindly contact us at www.gapsos.com